Vinflunine in the Treatment of Upper Tract Urothelial Carcinoma - Subgroup Analysis of an Observational Study

Heers H, De Geeter P, Goebell P, Matz U, De Schultz W, Edlich B, Retz M, Hegele A (2017)


Publication Type: Journal article

Publication year: 2017

Journal

Book Volume: 37

Pages Range: 6437-6442

Journal Issue: 11

DOI: 10.21873/anticanres.12098

Abstract

Background/Aim: Despite an expected prognostic disadvantage for upper tract versus lower tract metastatic urothelial carcinomas (UTUC/LTUC), only few studies have been conducted to elucidate potential differences in chemotherapy treatment. Patients and Methods: A post-hoc subgroup analysis of a non-interventional study investigating vinflunine after failure of a platinum-based chemotherapy in metastatic/locally advanced UC patients was performed. Results: A total of 18 and 59 out of 77 patients had UTUC and LTUC, respectively. The effectiveness of vinflunine treatment was comparable with an overall response rate of 22.2% and 23.7% respectively and a median progression-free survival of 2.76 months in both groups. Median overall survival was 5.0 months in UTUC compared to 8.2 months in the LTUC group (p=0.478). The safety profile was in accordance with previous vinflunine experiences, with a comparable frequency of adverse events in both groups. Conclusion: Vinflunine can be applied in the 2nd line for UC regardless of the primary tumor localization.

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Heers, H., De Geeter, P., Goebell, P., Matz, U., De Schultz, W., Edlich, B.,... Hegele, A. (2017). Vinflunine in the Treatment of Upper Tract Urothelial Carcinoma - Subgroup Analysis of an Observational Study. Anticancer Research, 37(11), 6437-6442. https://doi.org/10.21873/anticanres.12098

MLA:

Heers, Hendrik, et al. "Vinflunine in the Treatment of Upper Tract Urothelial Carcinoma - Subgroup Analysis of an Observational Study." Anticancer Research 37.11 (2017): 6437-6442.

BibTeX: Download